Vipshop Holdings Down Over 15%, on Pace for Largest Percent Decrease Since November 2021 — Data Talk
Vipshop Holdings Ltd Sponsored ADR (VIPS) is currently at $11.90, down $2.13 or 15.16%
--Would be lowest close since Dec. 1, 2022, when it closed at $11.43
--On pace for largest percent decrease since Nov. 18, 2021, when it fell 17.99%
--Currently down two consecutive days; down 15.94% over this period
--Worst two day stretch since the two days ending March 11, 2022, when it fell 17.69%
--Down 12.79% month-to-date
--Down 33.02% year-to-date
--Down 73.9% from its all-time closing high of $45.58 on March 23, 2021
--Down 26.03% from 52 weeks ago (Aug. 22, 2023), when it closed at $16.08
--Down 39.09% from its 52-week closing high of $19.53 on Feb. 28, 2024
--Would be a new 52-week closing low
--Traded as low as $11.86; lowest intraday level since Dec. 2, 2022, when it hit $11.23
--Down 15.41% at today's intraday low; largest intraday percent decrease since Nov. 18, 2021, when it fell as much as 19.79%
All data as of 12:00:39 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 20, 2024 12:19 ET (16:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks